Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Revvity Inc. (NYSE:RVTY)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on September 4th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Revvity Stock Down 0.6%

Shares of Revvity stock traded down $0.92 during trading on Wednesday, reaching $154.16. The company’s stock had a trading volume of 214,991 shares, compared to its average volume of 1,498,643. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The company has a market cap of $17.20 billion, a price-to-earnings ratio of 73.61, a P/E/G ratio of 2.83 and a beta of 1.06. The company has a 50-day simple moving average of $134.17 and a two-hundred day simple moving average of $112.19. Revvity Inc. has a 1-year low of $81.22 and a 1-year high of $166.25.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.21 by $0.20. The firm had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. Revvity’s revenue was down 1.3% on a year-over-year basis. During the same period last year, the firm posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Insiders Place Their Bets

In other news, insider Tajinder Vohra sold 7,330 shares of Revvity stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. The trade was a 52.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the transaction, the insider directly owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 9,130 shares of company stock valued at $1,290,745. Company insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. increased its holdings in Revvity by 5.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock valued at $231,000 after buying an additional 106 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Revvity by 17.0% during the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares in the last quarter. Angeles Wealth Management LLC boosted its position in Revvity by 2.0% during the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock worth $646,000 after purchasing an additional 112 shares in the last quarter. Tema ETFs LLC boosted its position in Revvity by 8.1% during the second quarter. Tema ETFs LLC now owns 1,946 shares of the company’s stock worth $217,000 after purchasing an additional 145 shares in the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in Revvity by 4.0% in the first quarter. Glenmede Trust Co. NA now owns 4,696 shares of the company’s stock valued at $411,000 after purchasing an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Analyst Ratings Changes

RVTY has been the topic of several research reports. KeyCorp upped their target price on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Sanford C. Bernstein began coverage on Revvity in a research report on Friday, June 26th. They set a “market perform” rating and a $115.00 price target for the company. Zacks Research raised Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. TD Cowen increased their price target on shares of Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Five equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $124.43.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Revvity

Revvity, Inc (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.